454 related articles for article (PubMed ID: 29602981)
1. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
[TBL] [Abstract][Full Text] [Related]
2. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.
Li Z; Li H; Wang C; Jiao Z; Xu F; Sun H
BMC Pharmacol Toxicol; 2021 May; 22(1):26. PubMed ID: 33947475
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
[TBL] [Abstract][Full Text] [Related]
7. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data.
Germovsek E; Osborne L; Gunaratnam F; Lounis SA; Busquets FB; Standing JF; Sinha AK
J Antimicrob Chemother; 2019 Apr; 74(4):1003-1011. PubMed ID: 30668696
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.
Anderson BJ; Allegaert K; Van den Anker JN; Cossey V; Holford NH
Br J Clin Pharmacol; 2007 Jan; 63(1):75-84. PubMed ID: 16869817
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and dose optimization of vancomycin in neonates.
Lee SM; Yang S; Kang S; Chang MJ
Sci Rep; 2021 Mar; 11(1):6168. PubMed ID: 33731764
[TBL] [Abstract][Full Text] [Related]
11. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
Li Z; Chen Y; Li Q; Cao D; Shi W; Cao Y; Wu D; Zhu Y; Wang Y; Chen C
Eur J Clin Pharmacol; 2013 Jun; 69(6):1223-33. PubMed ID: 23354809
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
16. Improved vancomycin dosing in children using area under the curve exposure.
Le J; Bradley JS; Murray W; Romanowski GL; Tran TT; Nguyen N; Cho S; Natale S; Bui I; Tran TM; Capparelli EV
Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.
Marqués-Miñana MR; Saadeddin A; Peris JE
Br J Clin Pharmacol; 2010 Nov; 70(5):713-20. PubMed ID: 21039765
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease.
Wang J; Li SC; Ye Q; Gao LL; Nie YM; Xu H; Wu M; Cao P; Wang Y
J Clin Pharmacol; 2020 Sep; 60(9):1220-1230. PubMed ID: 32488878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
